showing 1-10 of 135
AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new director of the NIH’s National Institute of Allergy and infectious Disease (NIAID). Dr. Marrazzo brings unparalleled leadership and research expertise to this pivotal role at NIAID, which oversees some of the largest investments to advance research on HIV and sexually transmitted infections in the world, at such a critical moment in global health science and politics.
AVAC strongly condemns Uganda’s new Anti-Homosexuality Act of 2023 that President Yoweri Museveni signed into law and stands in solidarity with the LGBTQIA+ community in Uganda.
AVAC Condemns Court Decision that Tramples Human Rights, Endangers Evidence-Based Medical Care and Sets a Dangerous Precedent
AVAC strongly condemns the decision by a federal judge in Texas who issued an unprecedented preliminary injunction that suspends the US Food and Drug Administration’s (FDA) approval of mifepristone, a safe and effective abortion medication...
Hundreds of HIV prevention advocates nationwide convened on Tuesday to discuss the implications of Judge Reed O’Connor’s ruling in the Texas Braidwood v. Becerra case that could impact access to PrEP and other preventive health interventions for...
AVAC Condemns Court Decision that Endangers Access to PrEP and Other Critical, Life-Saving Prevention Services
This ruling will not only affect HIV prevention services, but endangers access to contraception, vaccinations, routine health screenings and a wide range of prevention services.
AVAC condemns the legislation and stands in solidarity with the LGBTQIA+ community in Uganda who face threats to their lives, draconian prison terms, and even the prospect of death sentences.
Janssen Pharmaceutical Companies of Johnson & Johnson and partners announced that the Mosaico study, a large-scale HIV vaccine efficacy study also known as HVTN 706/HPX3002, was stopped early for non-efficacy.
Renewed Commitment to Expanding Access to All Existing HIV Prevention Options Must be a Global Priority Contact Kay Marshall, +1 (347) 249-6375, email@example.com January 18, 2023 — Today, Janssen Pharmaceutical Companies of Johnson &...
Movement for Equitable PrEP Access Gains Momentum Ahead of World AIDS Day Contact Jeremiah Johnson, Jeremiah@PrEP4All.org Rachel Klein, firstname.lastname@example.org November 29, 2022. Washington, DC—Over 6000 individuals and 300 organizations representing...
AVAC Condemns Court Decision that Tramples Human Rights, Reinforces Homophobia and Denies Life-Saving PrEP Drugs to Individuals in Texas
As a global organization dedicated to health as a human right, to social justice, and to individual autonomy and choice, AVAC condemns the decision by a federal judge in Texas who ruled in favor of a historically homophobic, misogynistic, and...
showing 1-10 of 135